INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST

NCATS 基因治疗测试的体内和离体免疫原性分析

• 批准号: 10891948
• 负责人: max moore
• 金额: $ 44.26万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-03 至 2026-07-02
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10891948
• 关键词: INSILICO; EX; VIVO; IMMUNOGENICITY; ANALYSIS

The Therapeutic Development Branch (TDB) in the Division of Preclinical Innovation (DPI) of NCATS advances novel therapeutics and technologies through preclinical and clinical stages of development. TDB initiated NCATS’ collaborative Rare Disease Platform Vector Gene Therapy (PaVe-GT) program. The program involves preclinical development and clinical evaluation of gene therapy products for rare diseases. In-silico and Ex-vivo analysis of the candidates is essential in de-risking the potential failure of the candidate in human subjects.

NCATS 临床前创新部门 (DPI) 的治疗开发部门 (TDB) 通过临床前和临床开发阶段推进新的治疗方法和技术，并启动了 NCATS 合作的罕见病平台载体基因治疗 (PaVe-GT) 项目。涉及罕见疾病基因治疗产品的临床前开发和临床评估，对候选药物进行体内和离体分析对于降低候选药物在人类中潜在失败的风险至关重要。科目。